BioSpace News Archive

Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine.

Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine

Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines.

The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign (TM) group of companies, which provide skilled nursing services, senior living services, rehabilitative care services and other healthcare services, announced today that it expects to issue its third quarter 2020 financial results on Wednesday, October 28, 2020. Conference Call Ensign invites current and prospective investors to tune into a live webcast

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, announced new hire grants totaling an aggregate of 58,800 inducement restricted stock awards to eleven employees.

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company’s Board of Directors. Mr. Spence will serve as a member and chair of the Compensation Committ

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M.D. as Senior Vice President & Chief Medical Officer (CMO). Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical

LSO remains concerned by today’s release of the final PMPRB guidelines implementing the federal government’s patented medicine price controls. The final guidelines create a highly risky and uncertain pathway for commercializing new medicines and vaccines in Canada. LSO President and CEO Jason Field wants to ask the Government of Canada “why did it take four months for the PMPRB to publish guidelines that contain no sub

iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft ® Axxent ® Electronic Brachytherapy (eBx ® ) System ® at the American Society for Radiation Oncology ( ASTRO ) Virtual Annual Meeting, October 24-28, 2020. Researchers will present new data supporting the Xoft System for the treatment of early-s

Interim d ata on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures Interim data from full patient population to be presented during ASTRO Late-breaking Special Session October 27